Introduction
============

The pathogenesis of irritable bowel syndrome (IBS) is complex and is believed to be multifactorial, involving the diet, an altered neuroendocrine system, abnormal intestinal microbiota, genetics and low-grade inflammation ([@b1-etm-0-0-3491]). More than 60% of patients with IBS associate their symptom development to diet ([@b2-etm-0-0-3491]--[@b4-etm-0-0-3491]). The most important dietary triggers are insoluble fiber and the rapidly fermentable but poorly absorbed carbohydrates termed fermented oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) ([@b5-etm-0-0-3491]--[@b9-etm-0-0-3491]).

Enteroendocrine cells are scattered among the various types of epithelial cells lining the gastrointestinal (GI) lumen ([@b10-etm-0-0-3491]--[@b13-etm-0-0-3491]). Patients with IBS have abnormal densities of enteroendocrine cells in various segments of the GI tract ([@b14-etm-0-0-3491]--[@b31-etm-0-0-3491]). Following dietary guidance about a low-FODMAP diet and changing the proportions of fat, protein, and carbohydrates in their diet, patients with IBS reportedly experience improvements in their IBS symptoms and quality of life ([@b32-etm-0-0-3491]) along with normalization of the densities of several types of enteroendocrine cells in the stomach ([@b33-etm-0-0-3491],[@b34-etm-0-0-3491]) and the large intestine ([@b35-etm-0-0-3491],[@b36-etm-0-0-3491]). The density of the total enteroendocrine cells as detected by chromogranin A (CgA) in the ileum also changes following dietary guidance ([@b37-etm-0-0-3491]). However, the types of enteroendocrine cells that are affected in these interventions are not clear. The present study was therefore undertaken to determine the types of ileal enteroendocrine cells that are affected following dietary guidance in the same cohort of patients with IBS.

Materials and methods
=====================

### Patients and controls

Male and female patients aged 18--70 years who were referred to the Division of Gastroenterology at the Stord Hospital (Stord, Norway) were included in the study. All of the patients fulfilled Rome-III criteria ([@b38-etm-0-0-3491]) for an IBS diagnosis. The exclusion criteria included pregnant or lactating women, and the presence of severe psychiatric or organic/systemic diseases, drug abuse and previous abdominal surgery (except for appendectomy, cesarean section and hysterectomy).

A group of 10 subjects (7 females and 3 males) with a mean age of 51 years (age range, 26--70 years) were included in the study as controls. Subjects in the control group did not present symptoms associated with IBS. These control subjects underwent colonoscopy due to health concerns not associated with IBM, including diagnosis of a family member with cancer of the GI tract (*n*=6) or a history of GI bleeding (*n*=4) where the source of bleeding was identified as hemorrhoids (*n*=3) or angiodysplasia (*n*=1).

The study was performed in accordance with the Declaration of Helsinki ([@b39-etm-0-0-3491]) and was approved by the local Committee for Medical Research Ethics in Western Norway (no. 2010/2650-2). All of the patients provided both oral and written consents to participate.

### Study design

In total, 46 patients (35 females and 11 males) were initially included in the study. Their mean age was 35 years (age range, 18--69 years). All of the patients received physical examinations and blood tests to exclude inflammation, infection, and other organic diseases. The patients also received a total of three sessions of individualized dietary guidance given by a nurse experienced in diet and IBS. The sessions lasted for 45 min each and were provided at intervals of at least 2 weeks ([Fig. 1](#f1-etm-0-0-3491){ref-type="fig"}). The patients were examined with colonoscopies prior to the first session and at 3--9 months (median, 4 months) following the last session of dietary guidance.

### Individualized dietary guidance

Dietary guidance was delivered orally using charts, and in written illustrations. The main focus of the first session was to provide general information regarding IBS, and to emphasize the importance of a regular eating pattern and the foodstuffs that worsen IBS symptoms such as poorly absorbable FODMAPs and insoluble dietary fiber. The patients were allowed to consume lactose-free milk and other lactose-free dairy products during the study. For a period of 2 weeks, the patients were instructed to test alternating diets that were rich and then poor in protein, fat and carbohydrates, each for 3--4 days. During this period the patients had to register in a diary their daily consumption of food and fluids (times and types) in addition to any associated symptoms, including the frequency and degree of abdominal pain and abdominal distension along with the stool frequency and consistency. No food supplements containing probiotics, antibiotics or other medications were allowed during the study, with the exception of where specified otherwise.

During the second session, the information given during the first session was briefly repeated. The nurse focused on using the information from the diary of the patient to identify the foodstuffs that triggered the IBS symptoms. Based on this information the patients were instructed to alter the proportions of protein, fat, and carbohydrates, to avoid FODMAP-rich foodstuffs as well as insoluble fiber, and to consume vegetables and fruits containing lower amounts of FODMAPs and insoluble fiber.

In the third session, each patient gave feedback regarding the dietary guidance to the nurse. With the help of the nurse, a suitable diet was designed for the patient to follow until the end of the study.

### Dietary assessment

The dietary intake was assessed using the Norwegian Mother and Child Study food frequency questionnaire (MoBa FFQ; [www.fhi.no/dokumenter/011fbd699d.pdf](www.fhi.no/dokumenter/011fbd699d.pdf)) ([@b40-etm-0-0-3491]), which reports the frequency and the sizes of food meal portions and beverages consumed during a certain period of time. The nutrient content of the diet was calculated using FoodCalc ([@b41-etm-0-0-3491]). The MoBa FFQ inquires about the consumption of 225 foodstuffs and also identifies the dietary habits of the subject, including the consumption of any oral supplements, according to typical Norwegian meal patterns. The questionnaire was developed and validated by the Norwegian Institute of Public Health in Oslo, Norway ([@b42-etm-0-0-3491],[@b43-etm-0-0-3491]). The patients completed the MoBa FFQ form prior to the first session and again ≥3 months following the third session of individualized dietary guidance. The forms were delivered on the same day on which a colonoscopy was scheduled ([@b32-etm-0-0-3491]).

### Colonoscopy

Colonoscopy was performed on both the patients and controls following preparation of their bowels via consumption of sodium picosulfate (Picoprep^®^; Ferring Pharmaceuticals, Saint-Prex, Switzerland) the day before the procedure. Four biopsies were taken from the ileum during the colonoscopy.

### Histopathology and immunohistochemistry

The biopsy samples were fixed overnight in 4% buffered paraformaldehyde (cat. no. 329847; Den Norske Eterfabrikk, Oslo, Norway) and embedded in paraffin (Cellwax; GCA-0305-00A; Cellpath Ltd., Newtown, Powys, UK). The tissue samples were then sectioned at a thickness of 5 µm using Leica SM2000 R Sliding microtome (Leica Biosystems Nussloch GmbH, Heidelberger, Germany) and placed on the slides, with each slide containing two tissue samples sectioned at 50 µm apart (distance in the paraffinated samples). The tissue sections were stained with hematoxylin (Cellpath Ltd.) and eosin (Merck KGaA, Darmstadt, Germany), and immunostained using the avidin-biotin complex (ABC) method with a Vectastain ABC kit (cat. no. PK-4000; Vector Laboratories, Inc., Burlingame, CA, USA) and the chromogen 3,3′-diaminobenzidine peroxidase substrate (DAB) kit (cat. no. SK-4105; Vector Laboratories, Inc.) as described previously ([@b40-etm-0-0-3491]). The tissue sections were hydrated and immersed in 0.01% hydrogen peroxide in phosphate-buffered saline (PBS; pH=7.4) for 10 min in order to inhibit endogenous peroxidase activity. Following washing with PBS, the tissue sections were treated with 1% bovine serum albumin for 30 min to block non-specific binding sites, followed by incubation with the primary antibody at room temperature for 1 h. The following primary antisera/antibodies were used: Monoclonal mouse anti-serotonin (cat. no. 5HT-209; Dako, Glostrup, Denmark), polyclonal anti-porcine peptide YY (PYY; cat. no. PYY 11A; Alpha-Diagnostic International, Inc., San Antonio, TX, USA), polyclonal rabbit anti-synthetic human pancreatic polypeptide (PP; cat. no. 114; Diagnostic Biosystems, Pleasanton, CA, USA), polyclonal rabbit anti-porcine glicentin/glucagon (also known as oxyntomodulin; cat. no. BP508; Acris Antibodies, Herford, Germany), and polyclonal rabbit anti-synthetic human somatostatin (cat. no. A566; Dako); these antibodies were each diluted to 1:1,500, 1:1,000, 1:800, 1:400 and 1:200, respectively.

The sections were then washed in PBS and incubated with biotinylated swine anti-mouse immunoglobulin G (Dako) diluted to 1:200 for 30 min at room temperature. Following washing in PBS buffer, the tissue sections were incubated for 30 min with avidin-biotin-peroxidase complex (Vector Laboratories) diluted to 1:100, and then submerged in DAB and counterstained with hematoxylin.

### Computerized image analysis

The density of each type of enteroendocrine cell in the ileum of patients with IBS and the controls was measured using Olympus Cell D software (version 5.1; Olympus, Tokyo, Japan). The number of enteroendocrine cells and the area of epithelial cells were measured in 10 randomly selected fields per slide, using Olympus BX50 DIC light microscope (Olympus, Oslo, Norway) at a magnification of ×40. Each field represented a tissue area of 0.14 mm^2^. The density of the enteroendocrine cells was expressed as the number of cells/mm^2^ of epithelium. The data from the fields were tabulated, computed, and automatically analyzed statistically. The quantification was conducted by the same scientist (Dr Tarek Mazzawi) while he was blinded to the identity of the tissue sections.

### Statistical analysis

Statistical analysis was performed using GraphPad Prism version 6 (GraphPad Software Inc., La Jolla, CA, USA). The data are presented as mean ± standard error of the mean values. Comparisons of the gender and age between the controls and the patients were conducted using Fisher\'s exact test and a Mann-Whitney test, respectively. Paired *t*-tests were used to compare the data from patients prior to and following dietary guidance. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patients and controls

In total, 46 patients were included in the study and received individualized dietary guidance, of which 14 (9 females and 5 males) with a mean age of 33 years (age range, 21--44 years) completed the study ([Fig. 1](#f1-etm-0-0-3491){ref-type="fig"}). In three of the original 46 patients (2 females and 1 male) it was technically difficult to intubate the ileocecal valve during colonoscopy, and so only 11 patients (7 females and 4 males) with a mean age of 33 years (age range, 24--44 years) were included in the final study analysis. The gender distribution did not differ significantly between the patients and controls (P=1), whereas the age distribution did (P=0.009). The demographic characteristics of the subjects are summarized in [Table I](#tI-etm-0-0-3491){ref-type="table"}.

Four of the 11 patients who completed the study used one or a combination of the following: Proton-pump inhibitors (*n*=2), thyroxin-substitution tablets (*n*=2), asthma inhalator (*n*=1), angiotensin II receptor antagonist antihypertension tablets (*n*=1), anti-allergy tablets (*n*=3), contraceptive pills (*n*=2), and antidepressant/anxiolytic tablets (*n*=2). These patients were instructed not to take any kind of proton-pump inhibitors or antacids for 1 week prior to beginning the study or during the study.

### Dietary assessment

The dietary changes in the current study are described in detail elsewhere ([@b32-etm-0-0-3491]). Briefly, the total consumption of daily fruits and vegetables rich in FODMAPs decreased significantly from 16.2±5.3 g prior to receiving dietary guidance to 9.2±3.2 g following dietary guidance (P=0.02). However, no significant change was observed in the total daily consumption of fiber prior to (27.4±2.5 g) and following (23.1±2.2 g) dietary guidance (P=0.09) ([@b32-etm-0-0-3491]).

### Colonoscopy, histopathology, and immunohistochemistry

The ileum was both macroscopically and microscopically normal in both the patients and controls. Serotonin-, PYY-, PP-, oxyntomodulin (enteroglucagon)-, and somatostatin-immunoreactive cells were found predominantly in the crypts of the ileum in all subjects (patients and controls). These cells were either basket-or flask-shaped. The numbers of PP-, oxyntomodulin (enteroglucagon)-, and somatostatin-immunoreactive cells were too low to be reliably quantified in the examined biopsy material.

### Computerized image analysis

#### Serotonin

The density of serotonin-immunoreactive cells in the controls was 35.5±5.7 cells/mm^2^. The density of these cells in patients with IBS was 38.7±7.1 cells/mm^2^ prior to dietary guidance and 22.3±2.6 cells/mm^2^ following dietary guidance ([Figs. 2](#f2-etm-0-0-3491){ref-type="fig"} and [3](#f3-etm-0-0-3491){ref-type="fig"}). The densities of serotonin-immunoreactive cells in the patients with IBS moved closer to the mean values within the 95% confidence interval of the controls following dietary guidance. The paired *t*-test indicated a significant decrease in the density of serotonin-immunoreactive cells in IBS patients following dietary guidance (P=0.046).

#### PYY

The density of PYY-immunoreactive cells in the controls was 16.7±2.8 cells/mm^2^. The densities of these cells in patients with IBS prior to and following dietary guidance were 20.2±5.1 and 21.3±2.7 cells/mm^2^, respectively ([Figs. 4](#f4-etm-0-0-3491){ref-type="fig"} and [5](#f5-etm-0-0-3491){ref-type="fig"}). The densities of PYY-immunoreactive cells in the patients with IBS were closer to the mean values within the 95% confidence interval of the controls following dietary guidance. The paired *t*-test showed no significant change in the density of PYY-immunoreactive cells in patients with IBS following dietary guidance (P=0.86).

Discussion
==========

Dropout rates of ≤48% have been reported in previous clinical studies involving IBS ([@b6-etm-0-0-3491],[@b45-etm-0-0-3491]--[@b48-etm-0-0-3491]). The current study had an even higher dropout rate, which was likely due to the demanding study design that included undergoing two colonoscopies and having to follow a strict diet for a minimum of 3 months. The majority of the patients withdrew their consents when they experienced symptom improvement following dietary guidance, and due to their unwillingness to participate again in an invasive examination, namely a second colonoscopy. Additional factors further increased the dropout rate to 76%, including the exclusion of some patients following diagnosis with organic diseases, pregnancy, moving abroad, and technically difficult colonoscopies. Nevertheless, although only a small number of patients completed this study, the changes in diet among these patients affected the enteroendocrine cells of the ileum in the same way as the dietary changes affected other investigated segments of the GI tract in previous studies ([@b33-etm-0-0-3491]--[@b37-etm-0-0-3491]). It is worth noting that neither age nor gender affects the densities of the intestinal enteroendocrine cells ([@b11-etm-0-0-3491],[@b35-etm-0-0-3491],[@b49-etm-0-0-3491]).

The enteroendocrine cells project specific microvilli that interact with the GI luminal contents (particularly with nutrients) and respond by releasing specific hormones that regulate various functions of the GI tract ([@b12-etm-0-0-3491],[@b50-etm-0-0-3491]--[@b58-etm-0-0-3491]). Serotonin stimulates the intestinal motility, accelerates intestinal transit ([@b59-etm-0-0-3491]--[@b67-etm-0-0-3491]), and activates the submucosal sensory branch (termed the Meissner\'s plexus) of the enteric nervous system that carries sensation from the GI tract to the central nervous system and modulates the visceral sensitivity of the GI tract ([@b17-etm-0-0-3491],[@b59-etm-0-0-3491],[@b63-etm-0-0-3491]--[@b65-etm-0-0-3491]). PYY is a major regulator of the 'ileal brake' and stimulates the absorption of water and electrolytes ([@b17-etm-0-0-3491],[@b68-etm-0-0-3491]).

A previous study involving the same cohort of patients with IBS investigated in the present study ([@b37-etm-0-0-3491]) demonstrated that the total enteroendocrine cells of the ileum, as detected by CgA, changed significantly following dietary guidance. These changes may be attributed to changes in the densities of serotonin- and PYY-immunoreactive cells. The densities of these cells became similar to those of the control subjects after the patients received dietary guidance. There is a dynamic interaction between foodstuffs and enteroendocrine cells ([@b69-etm-0-0-3491]). These cells have a rapid turnover rate from stem cells of \~2--6 days ([@b70-etm-0-0-3491],[@b71-etm-0-0-3491]). It can be speculated that a change of diet following dietary guidance may alter the differentiation of enteroendocrine cells and explain the observed changes in the densities of enteroendocrine cells in the ileum as well as the other parts of the GI tract in patients with IBS.

In conclusion, the cumulative changes in the enteroendocrine cells throughout the GI tract, namely in the stomach ([@b33-etm-0-0-3491],[@b34-etm-0-0-3491]), the small intestine ([@b37-etm-0-0-3491]), and the large intestine ([@b35-etm-0-0-3491],[@b36-etm-0-0-3491]), in patients with IBS following dietary guidance may have contributed to the improvements in the symptoms and quality of life of the patients with IBS that were observed during the present study, results which were concordant with those of a previous report ([@b32-etm-0-0-3491]). The findings of the present study highlight the role of the enteroendocrine cells in the pathophysiology of IBS and the usage of dietary guidance and diet manipulation as a first line step in the management of IBS symptoms.
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![Densities of serotonin-immunoreactive cells in the ileum of patients with IBS prior to and following dietary guidance. The dashed lines labeled 'a' and 'c' indicate the upper and lower limits of the 95% confidence interval for the serotonin cell density in the control subjects, respectively, whereas line 'b' indicates the mean serotonin cell density. \*P\<0.05, vs. the patients with IBS prior to dietary guidance. IBS, irritable bowel syndrome.](etm-12-03-1398-g01){#f2-etm-0-0-3491}

![Serotonin-immunoreactive cells in the ileum of a (A) control subject, and of a patient with irritable bowel syndrome (B) prior to and (C) following dietary guidance using a light microscope at magnification of ×40.](etm-12-03-1398-g02){#f3-etm-0-0-3491}

![Densities of PYY-immunoreactive cells in the ileum of patients with IBS prior to and following dietary guidance. The dashed lines labeled 'a' and 'c' indicate the upper and lower limits of the 95% confidence interval for the PYY cell density in the control subjects, respectively, whereas line 'b' indicates the mean PYY cell density. IBS, irritable bowel syndrome. PYY, peptide YY.](etm-12-03-1398-g03){#f4-etm-0-0-3491}

![PYY-immunoreactive cells in the ileum of a (A) control subject, and of a patient with irritable bowel syndrome (B) prior to and (C) following dietary guidance using a light microscope at magnification of ×40. PYY, peptide YY.](etm-12-03-1398-g04){#f5-etm-0-0-3491}

###### 

Demographic characteristics of the study subjects.

  IBS subtype and controls   Number of patients   Age range and mean (years)     Females/males
  -------------------------- -------------------- ------------------------------ ---------------
  IBS-D                      5                    31--45 (37.0)                  2/3
  IBS-C                      4                    28--36 (31.0)                  3/1
  IBS-M                      2                    24--30 (27.0)                  2/0
  Controls                   10                   26--70 ([@b51-etm-0-0-3491])   7/3

IBS-D, irritable bowel syndrome-diarrhea predominant; IBS-C, irritable bowel syndrome-constipation predominant; IBS-M, irritable bowel syndrome-mixed.
